Herman Kado

Herman Kado

Auto-generated profile, based on publicly available information

Herman Kado

Department of Cardiovascular Medicine, Corewell Health William Beaumont Hospital, Royal Oak, MI (H.K., J.T.).

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
DDDavid Dexter
David Dexter
HKHerman Kado
Herman Kado
ASAbdullah Shaikh
Abdullah Shaikh
JSJonathan Schor
Jonathan Schor
SASuman Annambhotla
Suman Annambhotla
HMHamid Mojibian
Hamid Mojibian
We report in-hospital outcomes from the multicenter, prospective, single-arm ClotTriever Outcomes (CLOUT) registry, which enrolled up to 500 patients with proximal lower extremity deep vein thrombosis (DVT) treated with percutaneous mechanical thrombectomy using the ClotTriever System (Inari Medical). The CLOUT registry enrolled all-comer patients with DVT, irrespective of symptom duration, thrombus age, prior treatment of the current DVT, or bilateral thrombus. The primary effectiveness end point was defined as complete or near complete (≥75%) reduction in Marder score. Thrombus burden was assessed by an independent core laboratory. Mortality and serious adverse events, including device-relatedness, were adjudicated by an independent medical monitor. Here, safety and outcomes are evaluated through discharge. The median age was 61.9 years (IQR, 48.0-70.8), 50.5% were women, 24.9% had a history of DVT, and 23.2% had previously failed treatment of the current DVT. Nearly all procedures (99.4%) were performed in a single session with negligible procedural blood loss (median 40.0 mL; IQR, 20.0-50.0), and most patients (97.8%) required no subsequent intensive care unit monitoring. The primary effectiveness end point was achieved in 91.2% of limbs. Through discharge, 1 device-related serious adverse event (0.2%) occurred. Health status, as assessed by self-reported pain and circumferential measurements of limb edema, were significantly improved at discharge. Thrombectomy with the ClotTriever System is a safe and effective treatment for proximal lower extremity DVT, while also avoiding the need of intensive care. Early patient improvements are demonstrated, and follow-up is ongoing to 2 years.

1 November 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
SBSripal Bangalore
Sripal Bangalore
RTR. Dana Tomalty
R. Dana Tomalty
HKHerman Kado
Herman Kado
SSSameh Sayfo
Sameh Sayfo
ARAdam Raskin
Adam Raskin
VBVivian Lee Lee Bishay
Vivian Lee Lee Bishay
BACKGROUND: Mechanical thrombectomy offers a promising alternative to thrombolytic-based approaches for reducing thrombus burden and right heart strain in acute pulmonary embolism. This pivotal Food and Drug Administration–approval trial evaluated the safety and efficacy of the Symphony Thrombectomy System (Imperative Care, Inc, Campbell, CA) in acute intermediate-risk pulmonary embolism. METHODS: Patients with intermediate-risk pulmonary embolism (systolic blood pressure ≥90 mm Hg; right ventricle-to-left ventricle ratio >0.9) were enrolled without roll-ins. The primary safety end point was the rate of major adverse events within 48 hours, defined as a composite of all-cause major bleeding, device-related mortality, and serious device-related events, adjudicated by an academic independent safety board. The primary efficacy end point was the core laboratory–assessed mean change in right ventricle-to-left ventricle ratio from baseline to 48 hours. Prespecified performance goals were set for both. Exploratory end points included immediate postprocedure change in mean pulmonary artery pressure and change in modified Miller index at 48 hours. Safety was assessed in the intention-to-treat cohort and efficacy in the modified intention-to-treat cohort, excluding patients receiving nonstudy device treatments. RESULTS: Between December 2023 and May 2025, 109 patients were treated at 17 US centers (intention-to-treat), with 106 in the modified intention-to-treat cohort. The major adverse events rate was 0.9% (1/109), with an upper 97.5% CI of 5.7%, meeting the <15% safety goal ( P 0.20 performance goal ( P <0.001). Mean pulmonary artery pressure decreased from 29.1±7.2 to 22.2±6.6 mm Hg (24%) and the modified Miller index from 24.2±4.1 to 14.9±5.4 (38%), both P <0.001. CONCLUSIONS: These data support the safety and effectiveness of the Symphony Thrombectomy System in patients with acute intermediate-risk pulmonary embolism. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06062329.

25 January 2024 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
PDF file
MCMedhat Chowdhury
Medhat Chowdhury
CWCameron Whilter
Cameron Whilter
PAPhanindra Antharam
Phanindra Antharam
PRPritham Reddy
Pritham Reddy
HKHerman Kado
Herman Kado
MOMatthew Osher
Matthew Osher
The profunda femoral artery is an uncommon location for a pseudoaneurysm and is technically challenging to resolve with traditional techniques, such as ultrasound-guided compression or thrombin injection, owing to its deep anatomical location. Balloon-assisted thrombin injection (BATI) is a technique that has been shown to be effective using contralateral access for technically difficult pseudoaneurysms in high-risk surgical patients. We report a case of BATI using radial access in a patient with a profunda femoral artery pseudoaneurysm.

1 March 2013 in JACC
Verified
Journal Article
Closed access
APAmbar Patel
Ambar Patel
HKHerman Kado
Herman Kado
SSSiva Suryadevara
Siva Suryadevara
Dominick Joseph AngiolilloDominick Joseph Angiolillo
Dominick Joseph Angiolillo
LBLyndon Box
Lyndon Box
LGLuis A. Guzman
Luis A. Guzman

3 November 2026 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
AAAymen Ahmed
Aymen Ahmed
SBSripal Bangalore
Sripal Bangalore
VBVivian Bishay
Vivian Bishay
RTR. Dana Tomalty
R. Dana Tomalty
HKHerman Kado
Herman Kado
AQArman Qamar
Arman Qamar